Hidradenitis suppurativa (Acne inversa) – Aktuelles zu Komorbidität und Therapie

Zusammenfassung

Lange unter der Rubrik „orphan disease“ gelistet, erfuhr die Hidradenitis suppurativa (HS) zuletzt mit der Zulassung von Adalimumab neue Aufmerksamkeit. Was mit einzelnen Knoten und Abszessen anfängt, endet unter mangelnder Behandlung nicht selten in ausgedehnter Fistelbildung und Vernarbung, die zum Teil mit erheblichen Bewegungseinschränkungen, sozialem Rückzug und Isolation einhergehen.

In Deutschland geht man derzeit von einer Prävalenz von etwa 1 % aus [1] [2]. Somit kommt diese multifaktoriell bedingte Erkrankung ähnlich häufig vor wie die Psoriasis, doch bekommt sie bei weitem nicht die gleiche Aufmerksamkeit. Vielleicht ist dies auch der Tatsache geschuldet, dass das Therapieangebot mit (noch) nur einer zugelassenen medikamentösen Therapie (Adalimumab) sehr viel kleiner ausfällt als beispielsweise das der Psoriasis.

Abstract

Long considered an orpan disease, Hidradenitis suppurativa (HS) has recently gained new attention since the approval of Adalimumab for its treatment. What generally starts with single nodules and abcesses, often ends in extensive fistulation and scarring if treated inadequately and is frequently accompanied by significant restrictions of mobility, social withdrawal and isolation.

It is presumed that in Germany the prevalence is about 1 % [1] [2], therefore this multifactorial disease has an incidence almost equal to that of psoriasis, although it doesn’t receive the same attention. This might be due to the fact that the available therapies with currently only one approved medical option (Adalimumab) are rather limited when compared to the numerous options for psoriasis.

• Literatur

• 1 Revuz JE, Canoui-Poitrine F, Wolkenstein P. et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601
• 2 Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-194
• 3 Jemec GB, Gniadecka M. Sebum excretion in hidradenitis suppurativa. Dermatology 1997; 194: 325-328
• 4 Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122: 763-769
• 5 Plewig G, Steger M. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G. Hrsg. Acne and related disorders. London: Martin Dunitz; 1989: 345-357
• 6 Danby FW, Jemec GB, Marsch WCh. et al. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 2013; 168: 1034-1039
• 7 Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996; 34: 994-999
• 8 von Laffert M, Helmbold P, Wohlrab J. et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19: 533-537
• 9 Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 1996; 135
• 10 van der Zee HH, Laman JD, Boer J. et al. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 2012; 10: 735-739
• 11 Margesson LJ, Danby FW. Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol 2014; 28: 1013-1027
• 12 van der Zee HH, de Ruiter L, van den Broecke DG. et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-1298
• 13 Riis PT, Søeby K, Saunte DM. et al. Patients With Hidradenitis Suppurativa Carry a Higher Systemic Inflammatory Load Than Other Dermatological Patients. Arch Dermatol Res 2015; 307: 885-889
• 14 Pascoe VL, Kimball AB. Hidradenitis suppurativa: current progress and future questions. JAMA Dermatol 2014; 150: 1263-1264
• 15 Shlyankevich J, Chen AJ, Kim GE. et al. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014; 71: 1144-1150
• 16 Wolkenstein P, Loundou A, Barrau K. et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623
• 17 Kimball AB, Jemec GB, Yang M. et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014; 171: 434-442
• 18 Zouboulis CC, Tzellos T, Kyrgidis A. et al. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. Br J Dermatol 2017; in press
• 19 Naldi L. Epidemiology. In: Jemec G, Revuz J, Leyden JJ. eds. Hidradenitis Suppurative. Berlin: Springer; 2006: 58-64
• 20 Dufour DN, Bryld LE. Hidradenitis suppurativa complicating naevus comedonicus: the possible influence of mechanical stress on the development of hidradenitis suppurativa. Dermatology 2010; 220: 323-325
• 21 Cesko E, Koerber A, Dissemond J. Smoking and obesity are associated factors in acne inversa: results of a retrospective investigation in 100 patients. Eur J Dermatol 2009; 19: 490-493
• 22 König A, Lehmann C, Rompel R. et al. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999; 198: 261-264
• 23 Hana A, Booken D, Henrich C. et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 2007; 80: 2214-2220
• 24 Kurzen H, Kurokawa I, Jemec GB. et al. What causes hidradenitis suppurativa?. Exp Dermatol 2008; 17: 455-472
• 25 Gold DA, Reeder VJ, Mahan MG. et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014; 70: 699-703
• 26 Miller IM, Ellervik C, Vinding GR. et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014; 150: 1273-1280
• 27 Egeberg A, Gislason GH, Hansen PR. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatol 2016; 152: 429-434
• 28 Craig A. Elmets, MD reviewing Egeberg A et al. JAMA Dermatol 2016 Feb 17 . http://www.jwatch.org/na40561/2016/03/15/increased-risk-cardiovascular-adverse-events-patients-with
• 29 Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 2007; 11: 125-131
• 30 Schneider-Burrus S, Witte-Haendel E, Christou D. et al. High Prevalence of back pain and axial spondyloarthropathy in patients with Hidradenitis Suppurativa. Dermatology 2016; 232: 606-612
• 31 Richette P, Molto A, Viguier M. et al. Hidradenitis suppurativa associated with spondyloarthritis -- results from a multicenter national prospective study. J Rheumatol 2014; 41: 490-494
• 32 Kurek A, Johanne Peters EM, Sabat R. et al. Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges 2013; 11: 743-750
• 33 Essmann S, Jemec G. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venerol 2011; 91: 328-332
• 34 Guillem P. Psychological support for patients with hidradenitis suppurativa. Berlin: EHSF Symposium; 2016
• 35 Verdolini R, Clayton N, Smith A. et al. Metformin for the treatment of Hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venererol 2013; 27: 1101-1108
• 36 Mühlstädt M, Bechara FG, Kunte C. Acne inversa (hidradenitis suppurativa). From diagnosis to therapy. Hautarzt 2013; 64: 55-61
• 37 Mrowietz U. Tagesnotiz. JDDG 2016; 14: 650
• 38 Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22: 325-328
• 39 Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39: 971-974
• 40 Gener G, Canoui-Poitrine F, Revuz JE. et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219: 148-154
• 41 Kimball AB, Okun MM, Williams DA. et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016; 375: 422-434
• 42 Gulliver W, Zouboulis C, Prens E. et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord 2016; 17: 343-351
• 43 Danby FW, Hazen PG, Boer J. New and traditional surgical approaches to hidradenitis suppurativa. J Am Acad Dermatol 2015; 73: 62-65
• 44 Mehdizadeh A, Hazen P, Bechara F. et al. Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis. J Am Acad Dermatol 2015; 73: 70-77
• 45 Falola R, DeFazio M, Anghel E. et al. What Heals Hidradenitis Suppurativa: Surgery, Immunosuppression, or Both?. Plast Reconstr Surg 2016; 138: 219-229